Clinical trial • Not applicable • Neurology
ROPIVACAINE for Anesthesia | Intensive care
Not applicable trial of ROPIVACAINE for Anesthesia | Intensive care.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Anesthesia | Intensive care
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 02-07-2024
- First CTIS Authorization Date
- 30-07-2024
Trial design
Randomised, two parallel arms: groupe al (anesthésie locale) - infiltration locale par 10 ml de lidocaïne 20 mg/ml non adrénalinée; groupe s (bloc serratus) - injection sous échoguidage de 30 ml ropivacaine 4,75 mg/ml.-controlled Not applicable trial across 1 site in France.
- Randomised
- Yes
- Comparator
- Two parallel arms: Groupe AL (Anesthésie locale) - infiltration locale par 10 mL de Lidocaïne 20 mg/mL non adrénalinée; Groupe S (Bloc Serratus) - Injection sous échoguidage de 30 mL Ropivacaine 4,75 mg/mL.
- Target Sample Size
- 70
- Trial Duration For Participant
- 1
Stratification factors
- Baseline pain (EN) category (1-3, 4-6, 7-10)
- Care unit/service
Eligibility
Recruits 70 Vulnerable population not selected. Patients under guardianship or curatorship or deprived of liberty are excluded. Inclusion requires 'Free and informed consent signed.'.
- Pregnancy Exclusion
- Pregnant, parturient or breastfeeding woman.
- Vulnerable Population
- Vulnerable population not selected. Patients under guardianship or curatorship or deprived of liberty are excluded. Inclusion requires 'Free and informed consent signed.'
Inclusion criteria
- {"criterion_text":"- Patient aged 18 or over, not intubated, spontaneously ventilating."}
- {"criterion_text":"- Free and informed consent signed."}
- {"criterion_text":"- Affiliate to a social security scheme."}
- {"criterion_text":"- Hospitalized in multipurpose intensive care unit including surgical resuscitation, cardiothoracic and respiratory resuscitation or continuing cardiothoracic and respiratory care services."}
- {"criterion_text":"- Requiring gas or fluid pleural drainage."}
Exclusion criteria
- {"criterion_text":"- Patient didn't agree to participate in the trial."}
- {"criterion_text":"- Patient under guardianship or curatorship or deprived of liberty."}
- {"criterion_text":"- Pregnant, parturient or breastfeeding woman."}
- {"criterion_text":"- Allergy and contraindication to Lidocaine or Ropivacaine."}
- {"criterion_text":"- Coagulation disorders."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Intensity of acute pain during pleural drainage (H0) by numerical scale (EN).","definition_or_measurement_approach":"Measured at H0 using a numerical scale (EN) during pleural drainage."}
Secondary endpoints
- {"endpoint_text":"- Intensity of acute pain by EN at rest and during exercise (forced inspiration) at the end of pleural drainage (H0).","definition_or_measurement_approach":"Measured at H0 using numerical scale (EN) at rest and during forced inspiration."}
- {"endpoint_text":"- Intensity of acute pain from EN at rest and during exercise (cough and forced inspiration) after drainage over the first 24 hours (H0, H1, H6, H24).","definition_or_measurement_approach":"Measured using EN at timepoints H0, H1, H6, H24 at rest and during cough and forced inspiration."}
- {"endpoint_text":"- Clinical tolerance at the end of drainage (H0): MAP HR, FR, SpO2.","definition_or_measurement_approach":"Clinical parameters measured at H0: mean arterial pressure (MAP), heart rate (HR), respiratory rate (FR), SpO2."}
- {"endpoint_text":"- Lung capacity in milliliters measured by the Voldyne (maximum inspired volume) H1, H6, H24.","definition_or_measurement_approach":"Maximum inspired volume measured by Voldyne at H1, H6, H24."}
- {"endpoint_text":"- Respiratory complications: - atelectasis = auscultation + radiography or ultrasound - nosocomial pneumonia = 3 clinicoradiological criteria compatible with radiological infiltrate + hyperthermia (>38 or <36°C) or leukocytes (>12000 or <4000 GB/mm3) + purulent aspirations or suggestive auscultation or hypoxemia.","definition_or_measurement_approach":"Respiratory complications defined as: atelectasis by auscultation plus radiography/ultrasound; nosocomial pneumonia defined by 3 clinicoradiological criteria plus hyperthermia or leukocyte criteria and purulent aspirations or evocative auscultation or hypoxemia."}
- {"endpoint_text":"- Use of tracheal intubation.","definition_or_measurement_approach":"Occurrence of tracheal intubation during follow-up."}
- {"endpoint_text":"- Early rehabilitation: time to first getting up, physiotherapy.","definition_or_measurement_approach":"Time to first ambulation and initiation of physiotherapy."}
- {"endpoint_text":"- Duration of drainage.","definition_or_measurement_approach":"Measured duration of pleural drainage."}
- {"endpoint_text":"- Duration of stay in intensive care.","definition_or_measurement_approach":"Length of ICU stay."}
- {"endpoint_text":"- Duration of installation of anesthesia.","definition_or_measurement_approach":"Time required to install anesthesia."}
Recruitment
- Planned Sample Size
- 70
- Recruitment Window Months
- 83
- Consent Approach
- Informed consent: 'Free and informed consent signed.' Consent must be provided and signed by the participant. Patients under guardianship or curatorship or deprived of liberty are excluded. A subject information and informed consent form for adults (L1) is listed.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 70
France
- Earliest CTIS Part Ii Submission Date
- 10-07-2024
- Latest Decision Or Authorization Date
- 30-07-2024
- Processing Time Days
- 20
- Number Of Sites
- 1
- Number Of Participants
- 70
Sites
- Site Name
- Centre Hospitalier Universitaire Amiens Picardie
- Department Name
- Pôle d’Anesthésie-Réanimation
- Principal Investigator Name
- Stéphanie MALAQUIN
- Principal Investigator Email
- malaquin.stephanie@chu-amiens.fr
- Contact Person Name
- Stéphanie MALAQUIN
- Contact Person Email
- malaquin.stephanie@chu-amiens.fr
- Number Of Participants
- 70
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire Amiens Picardie
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- ROPIVACAINE
- Active Substance
- ROPIVACAINE
- Modality
- Small molecule
- Routes Of Administration
- INFILTRATION
- Route
- INFILTRATION
- Starting Dose
- Injection sous échoguidage de 30 mL Ropivacaine 4,75 mg/mL
- Maximum Dose
- 225 mg
- Investigational Product Name
- LIDOCAINE HYDROCHLORIDE
- Active Substance
- LIDOCAINE HYDROCHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INFILTRATION
- Route
- INFILTRATION
- Starting Dose
- Infiltration locale par 10 mL de Lidocaïne 20 mg/mL non adrénalinée
- Maximum Dose
- 400 mg
- Investigational Product Name
- DEXAMETHASONE SODIUM PHOSPHATE
- Active Substance
- DEXAMETHASONE SODIUM PHOSPHATE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS
- Route
- INTRAVENOUS
- Starting Dose
- 8 mg
- Maximum Dose
- 8 mg
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke